✦ LIBER ✦

Reply to: “Cost-effectiveness of upcoming treatments for hepatitis C: We need to get the models right”

✍ Scribed by Younossi, Zobair M.; Henry, Linda; Singer, Mendel

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of upcoming treatment

✍ Tsochatzis, Emmanuel A.; Crossan, Catriona; Longworth, Louise 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 179 KB

1119 QUANTIFYING THE EXTENT OF CIRRHOSIS

✍ Innes, H.A.; Hutchinson, S.J.; Amanda, W.; Dillon, J.F.; Goldberg, D.J.; Mills, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Using competence network collaboration a

✍ Uwe Siebert; Gaby Sroczynski; Jürgen Wasem; Wolfgang Greiner; Ulrike Ravens-Sieb 📂 Article 📅 2005 🏛 Springer 🌐 French ⚖ 261 KB

PIN29 Cost Effectiveness Analysis of Add

✍ Ramachandran, S.; Mahabaleshwarkar, R.; Yang, Y. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

PGI18 Cost-Effectiveness of Boceprevir i

✍ S.C. Humphreys; E.H. Elbasha; S.A. Ferrante; M. Lion; C. O'Regan 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Cost Effectiveness Analysis of Boceprevi

✍ Athanasakis, K.; Karampli, E.; Retsa, M.P.; Theodoropoulou, T.; Kyriopoulos, J. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB